What is a stock summary page? Click here for an overview.
Business Description
Evoke Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US30049G1040
Description
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.64 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 0.73 | |||||
| Debt-to-EBITDA | -1.06 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -9.94 | |||||
| Beneish M-Score | -0.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9.4 | |||||
| 3-Year EBITDA Growth Rate | 58.6 | |||||
| 3-Year EPS without NRI Growth Rate | 58.3 | |||||
| 3-Year FCF Growth Rate | 62.7 | |||||
| 3-Year Book Growth Rate | -32.9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 52.11 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.64 | |||||
| 9-Day RSI | 57.27 | |||||
| 14-Day RSI | 47.38 | |||||
| 3-1 Month Momentum % | -36.28 | |||||
| 6-1 Month Momentum % | -46.98 | |||||
| 12-1 Month Momentum % | -46.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.66 | |||||
| Quick Ratio | 1.62 | |||||
| Cash Ratio | 1.31 | |||||
| Days Inventory | 525.19 | |||||
| Days Sales Outstanding | 61.05 | |||||
| Days Payable | 2134.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -87.1 | |||||
| Shareholder Yield % | -181.84 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.54 | |||||
| Operating Margin % | -50.79 | |||||
| Net Margin % | -52.23 | |||||
| FCF Margin % | -53.27 | |||||
| ROE % | -178.32 | |||||
| ROA % | -42.25 | |||||
| ROIC % | -89.22 | |||||
| 3-Year ROIIC % | 52.16 | |||||
| ROC (Joel Greenblatt) % | -3150 | |||||
| ROCE % | -160.52 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 5.47 | |||||
| PS Ratio | 0.3 | |||||
| PB Ratio | 0.54 | |||||
| Price-to-Tangible-Book | 0.54 | |||||
| EV-to-EBIT | 0.94 | |||||
| EV-to-EBITDA | 0.94 | |||||
| EV-to-Revenue | -0.45 | |||||
| EV-to-FCF | 0.84 | |||||
| Price-to-GF-Value | 0.22 | |||||
| Price-to-Net-Current-Asset-Value | 0.57 | |||||
| Price-to-Net-Cash | 1.23 | |||||
| Earnings Yield (Greenblatt) % | 106.38 | |||||
| FCF Yield % | -141.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EVOK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evoke Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10.248 | ||
| EPS (TTM) ($) | -4.713 | ||
| Beta | 0.22 | ||
| 3-Year Sharpe Ratio | -0.84 | ||
| 3-Year Sortino Ratio | -1.11 | ||
| Volatility % | 68.15 | ||
| 14-Day RSI | 47.38 | ||
| 14-Day ATR ($) | 0.252364 | ||
| 20-Day SMA ($) | 2.36672 | ||
| 12-1 Month Momentum % | -46.29 | ||
| 52-Week Range ($) | 1.94 - 12.3199 | ||
| Shares Outstanding (Mil) | 1.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evoke Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evoke Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Evoke Pharma Inc Frequently Asked Questions
What is Evoke Pharma Inc(EVOK)'s stock price today?
The current price of EVOK is $2.58. The 52 week high of EVOK is $12.32 and 52 week low is $1.94.
When is next earnings date of Evoke Pharma Inc(EVOK)?
The next earnings date of Evoke Pharma Inc(EVOK) is 2025-05-14 Est..
Does Evoke Pharma Inc(EVOK) pay dividends? If so, how much?
Evoke Pharma Inc(EVOK) does not pay dividend.
Guru Commentaries on NAS:EVOK
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers